FDA Clearance Tracker · P160038
Praxis Extended RAS Panel
Last checked: Nov 20, 2026Latest source record: Jun 29, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jun 29, 2017
Approval withdrawn
Time to decision
300 days
Received Sep 2, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P160038
- Device name
- Praxis Extended RAS Panel
- Applicant
- Illumina, Inc.
- Applicant location
- San Diego, CA
- Received
- Sep 2, 2016
- Decided
- Jun 29, 2017
- Decision
- Approval withdrawn
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 25 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Praxis Extended RAS Panel is a qualitative in vitro diagnostic test using targeted high throughput parallel sequencing for the detection of 56 specific mutations in RAS genes [KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4)] in DNA extracted from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The Praxis Extended RAS Panel is indicated to aid in the identification of patients with colorectal cancer for treatment with Vectibix® (panitumumab) based on a no mutation detected test result. The test is intended to be used on the Illumina MiSeqDx® instrument.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PQP. The earliest in FDA's data is P160018, decided Dec 19, 2016.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Illumina, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- TruSight Oncology ComprehensivePMA supplement
P230011-S006 · Decided Aug 14, 2026 · 269 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P230011 · Decided Aug 21, 2024 · 520 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.